



INTERNATIONAL JOURNAL OF PHARMACY AND ANALYTICAL RESEARCH

ISSN:2320-2831

IJP AR |Vol.7 | Issue 3 | July - Sep -2018
Journal Home page: www.ijpar.com

Research article

Open Access

Formulation and evaluation of dabigatran fast dissolving tablets by using polyplasdone xl-10 and primellose

Ausaf Butool*², Bibi Fareesa Banu², Tuba khan², Rufaida Farheen², Dr. Y Rajesh¹

¹Associate Professor Dept. of Pharmaceutical chemistry, Sultan-ul-uloom College of Pharmacy

²Sultan-ul-uloom College of Pharmacy, Banjara Hills, Hyderabad-500034, T.S

*Corresponding Author: Ausaf Butool

Email: ausafbutool@gmail.com

ABSTRACT

Dabigatran is an oral anticoagulant drug requiring rapid onset of action to exert desired pharmacological effect. It is a lipophilic (BCS Class-II) with little/no aqueous solubility, its absorption is dissolution rate limited. Increase in solubility of the drug is required to get rapid action. It has the half life of 14 hours and bioavailability in the body is 65% due to first pass metabolism. The purpose of this investigation is to develop fast dissolving tablet of Dabigatran to improve oral bioavailability for its immediate action for the treatment of stroke prevention in atrial fibrillation, the fast dissolving tablet was formulated by wet granulation technique using hydrophilic carrier like PEG-400 as solubilizer and POLYPLASDONE XL-10 and PRIMELLOSE used as super-disintegrant. The pre and post compression parameters were evaluated. From the dissolution profile it was concluded the tablet prepared by wet granulation technique, the formulation F6 containing 4% of PEG 4000 and 7.5% PRIMELLOSE showed 85.46% drug release due to its increase in porosity and wettability. From the DSC and FTIR study it was concluded that there was no possible drug and polymer interactions.

Keywords: Dabigatran, Hydrophilic carriers, Fast Dissolving tablets, Super-disintegrants.

INTRODUCTION

A tablet is a pharmaceutical dosage form of a medicament. It comprises a mixture of active substances and excipients usually in powdered form, pressed or compacted from a powder into a solid dose.

The excipients can include diluents, binders or granulating agents, glidants and lubricants to ensure efficient tableting; disintegrants to promote tablet breakup in the digestive tract; sweeteners or flavors to enhance taste; and pigments to make the tablets visually attractive.

A fast dissolving tablet dissolves or disintegrate in the oral cavity without the need of water or chewing. Most fast dissolving tablets must include substance to mask the taste of the active ingredients. [1] This masked active ingredient is then swallowed by the patients saliva along with the soluble and insoluble excipients. These are also called melt-in –mouth tablets, repellents, porous tablets, oro-dispersible, quick dissolving or rapid disintegrating tablets.[2]

Requirements

Having a pleasing mouth feel.

Have an acceptable taste masking property.


Be harder and less friable.

Leave minimal or no residue in mouth after administration.

Not affected by drugs properties.

Properties of dabigatran

Structure



Chemical Name

Ethyl N-{{[2-({[4-((E)-Amino{[(hexyloxy)carbonyl]imino}methyl)phenyl]amino}methyl)-1-methyl-1H-benzimidazole-5-yl]carbonyl.

Molecular Formula

$C_{34}H_{41}N_7O_5$

Molecular Weight

627.75gms/moles

Category

Stroke prevention in atrial fibrillation.

Protein Binding

34-35%

Biological half life

14 hours

Absorption


Peak plasma concentration were achieved in 6hrs.[3]

MECHANISM OF ACTION

Dabigatran, the main active principle in plasma, is a rapid acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in a coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

PROPERTIES OF POLYPLASDONE XL-10

Structure



IUPAC name:

1-ethenylpyrrolidine-2-one

Molecular weight:

111.143g/moles

Solubility:


Insoluble in water, though it still absorbs water and swells very rapidly generating a swelling force.

Functional category:

Disintegrant and stabilizer.

PROPERTIES OF PRIMELLOSE

Structure



Molecular formula:

$C_{28}H_{30}Na_9O_{27}$

Molecular weight:

982.4470

Physical state:

White to off white powder

Melting point:

More than 300

Boiling point:

More than 300

Solubility:

Slightly soluble in water. [4]

pharmacological effect. It is a lipophilic (BCS Class-II) drug with little/no aqueous solubility.

The purpose of this investigation is to develop fast dissolving tablets of dabigatran to improve oral bioavailability for its immediate action.

PLAN OF WORK

1. Preparation of calibration curve Dabigatran by spectrophotometrically.
2. Development of formulation.
 - a. Compatibility studies.
 - b. Evaluation of physical properties of powder mass.
 - c. Preparation of fast dissolving tablets using super-disintegrants
3. Evaluation of tablets.

OBJECTIVE

Dabigatran is an oral anticoagulant drug requiring rapid onset of action to exert desired

- a. In-vitro dissolution studies of fast dissolving tablets.
 - b. Evaluation of post compression parameters.
4. Characterization of prepared dabigatran tablets
- a. Fourier Transform Infrared Spectroscopy (FTIR).
 - b. Differential scanning calorimetry(DSC)
5. Stability study of optimized formulation.

Table 1: Instruments used

| S.no | Instruments | Company made |
|------|------------------------------|---------------------------|
| 1. | Hardness tester | Monsanto hardness tester. |
| 2. | Friability test apparatus | Roche friabilator |
| 3. | Tablet dissolution tester | Rolex |
| 4. | Tablet disintegrating tester | Rolex |
| 5. | Bulk density apparatus | SECOR |
| 6. | UV | Shimazdu |
| 7. | FTIR | Shimazdu |

Calibration Curve of Dabigatran in methanol

Determination of λ_{max}

The UV spectrophotometer was set to zero and the standard solution was scanned to obtain the maximum wavelength absorption against blank between wavelength of 200-400nm. The standard solution was scanned for absorbance maxima against blank. The maximum absorbance was found to be 330nm for methanol which was fixed as a wavelength for drug analysis. [5]

Procedure for calibration curve

2mg of Dabigatran was accurately weighed and dissolved in 50ml of methanol to make 400ppm. From this 4,6,8,10,12ppm aliquots were prepared and the absorbance was measured at λ_{max} of 316nm which follows linearity and obeys Beer-Lamberts Law.

Linearity graph of Dabigatran in methanol

From the calibration curve it was found that it shows linearity in the range of 4-12 μ g/ml with regression 0.999

Table 2: Calibration curve of Dabigatran in methanol

| Conc.(ppm) | Abs at 316nm |
|------------|--------------|
| 0 | 0 |
| 4 | 0.074 |
| 6 | 0.108 |
| 8 | 0.145 |
| 10 | 0.175 |
| 12 | 0.211 |

CALIBRATION CURVE OF DABIGATRAN IN 0.01N HCL

Determination of λ_{max}

The UV spectrophotometer was set to auto zero and the standard solution was scanned to obtain the maximum wavelength absorption absorbance against blank between wavelength of 200-400nm. The standard solution was scanned for absorbance maxima against blank. The maximum absorbance was found to be 360nm in 0.01N HCl, which was fixed as a wavelength for in vitro drug release.

Procedure for calibration curve

20mg of Dabigatran was accurately weighed and dissolved in 100ml in 0.01N HCl to make 200ppm. From this 4,6,8,10,12ppm aliquots were prepared and the absorbance was measured at 316nm which follows linearity and obeys Beer-Lamberts law. [6]

Linearity graph of Dabigatran in 0.01N HCl

From the calibration curve it was found that it shows linearity in the range of 4-12µg/ml with regression 0.999

Table 3: Calibration curve of dabigatran in 0.01N HCl

| Conc(ppm) | Abs at 360nm |
|-----------|--------------|
| 0 | 0 |
| 4 | 0.077 |
| 6 | 0.111 |
| 8 | 0.44 |
| 10 | 0.176 |
| 12 | 0.209 |

DEVELOPMENT OF FORMULATION

Procedure for wet granulation method of formulation F1 –F6

Preparation of binder solution

- Take pvpk-30 (binder) and dissolve in required volume of distilled water (10ml) the binder solution is prepared.
- Take drug and hydrophilic carrier PEG-4000 in a motor and pistil and triturate for 10 minutes, then add diluents like MCC, pearlitol SD-200 and half quantity of super-disintegrant mix thoroughly. Care should be taken to confirm the proper mixing of drug and super-disintegrant.

- Pour binder solution in that above solution to make wet or dough mass. The mass was passed through sieve no 10 to obtain wet granules.
- The wet granules were dried at 60⁰c for 15mins, then dried granules was passed through sieve no.20 to break the aggregates. And again dried at 60⁰c for 15min.
- Now add remaining half quantity of superdisintegrants and lubricants (talc and magnesium stearate) were passed through sieve no 80 dry and blended for 3mins.
- The prepared granules were subjected for compression using 8mm embossed flat punch.




Fig. 1, Table2: Calibration curve of Dabigatran in methanol




Fig. 2, Table3: Calibration curve of Dabigatran in 0.01N HCl

Table 4: Composition of sublingual tablets from formulation F1 to F6

| Drugs and Excipients(mg) | F1 | F2 | F3 | F4 | F5 | F6 |
|--------------------------|----|----|----|----|----|-----|
| Dabigatran | 50 | 50 | 50 | 50 | 50 | 50 |
| Avicel PH102 | 40 | 50 | 60 | 70 | 80 | 100 |
| Perlitol SD200 | 82 | 70 | 55 | 49 | 37 | 12 |
| PVPK-30 | 10 | 10 | 10 | 10 | 10 | 10 |
| PEG 4000 | 5 | 5 | 5 | 8 | 8 | 8 |
| Crospovidone | 8 | 10 | 15 | - | - | - |
| Primellose | - | - | - | 8 | 10 | 15 |
| Magnesium stearate | 3 | 3 | 3 | 3 | 3 | 3 |
| Talc | 2 | 2 | 2 | 2 | 2 | 2 |

Evaluation of physical properties of drug excipient mixtures

Angle of Repose

Angle of repose was determined by fixed height method to characterize the flow property of powder. A funnel with 10mm diameter of stem was fixed at a height of 2cm. over the platform. About 10gm of sample was slowly passed along the wall of the funnel till the tip of the pile formed touches

the stem of the funnel. A rough circle was drawn around the pile base and the radius of the powder cone was measured.

Angle of repose was calculated from the average radius using the following formula.

$$\theta = \tan^{-1} (h/r)$$

Where, θ = angle of repose

h = height of the pile

r = average radius of the powder cone.

Table 5: Relationship between % compressibility and flow ability

| % compressibility | Flow ability |
|-------------------|----------------|
| 5-12 | Excellent |
| 12-16 | Good |
| 18-21 | Fair possible |
| 23-35 | Poor |
| 33-38 | Very poor |
| <40 | Very very poor |

Bulk Density

Bulk density is determined by pouring gently 25gm of sample through a glass funnel into a 100ml graduated cylinder. The volume occupied by the sample was recorded. Bulk density was calculated.

Bulk density (g/ml)= weight of sample /volume occupied by the sample.

Tapped density

The tapped density was determined by pouring 25gm sample through a glass funnel into a 100ml graduated cylinder. The cylinder was tapped from the height of 2 inches until a constant volume was obtained. volume occupied by the sample after tapping was recorded and tapped density was calculated.

Tapped density (g/ml) = weight of sample / volume occupied by the sample

Compressibility (%)

It is also one of the sample methods to evaluate flow property of a powder by comparing the bulk density and tapped density. Useful empirical guide is given by the Carr's index.

Carr's Index= Tapped density – Bulk density/Tapped density x 100

Hausner ratio

It provides an indication of the degree of densification which could result from vibration of feed hopper.

Hausner ratio = tapped density / bulk density

Lower hausner ratio → Better flowability

Higher Hausner ratio → Poor flowability

Friability

Twenty tablets were weighed and placed in the roche friabilator test apparatus, the tablets were exposed to rolling and repeated shocks. Resulting from free falls within the apparatus. After 100 revolution, the tablets were dedusted and weighed again. The friability was determined as the percentage laws in weight of the tablets.

Friability (%) = 1-[weight of tablets after test/weight of tablet before test] x 100

Hardness

Hardness of tablets was measured using the Monsanto hardness tester.

Drug content

Three tablets from each formulation batch were powdered in a quantity equivalent to 5 mg of Dabigatran was transferred to 100ml of volumetric flask and diluted to 100ml with methanol. 15ml of the solution was taken and diluted to 100ml with methanol and absorbance was measured at 330nm. Concentration of Dabigatran in methanol is determined by using calibration curve.

Wetting Time

A piece of tissue paper (12cm x 10.75 cm) folded twice was placed in a small petridish (i.d. = 6.5cm) containing 6ml of 0.01N HCl. A tablet was placed on a paper , and the time for the complete wetting was measured.

In-vitro disintegration time

The tablet was placed in each tube, and the basket rack was positioned in a 1 litre beaker of 0.01N HCl at 35⁰ c ± 2⁰c. the time required for complete disintegration of tablet was noted.

Weight variation

20 tablets were selected randomly from each formulation, weighed individually and the average weight and % variation of tablet weight was calculated. [7]

CHARACTERIZATION OF DRUG AND EXCIPIENTS

Fourier Transform Infrared Spectroscopy (FT-IR)

The FTIR spectra were obtained using FTIR spectrometer (shimadzu). The sample were previously ground and mixed thoroughly with potassium bromide, an infrared transparent metrics in 1:5(sample:KBr) ratio, respectively. The KBr discs were prepared by compressing the powder at a pressure of 5 tones for 5 min in a hydraulic press. 45 scans were obtain at a resolution of 4 cm⁻¹ from 400-4500 cm⁻¹. [8]

Differential Scanning Calorimetry (DSC):

The DSC measurement were performed on a Pyris Diamond TG/DTA differential scanning

calorimeter with thermal analyzer. All accurately weighed samples about 5mg were placed in sealed aluminum pans. An empty aluminum was used as reference. [9]

Table 6: Physical properties of the tablets of formulations F1 to F6

| Formulation Batches | Angle of repose(θ) | Bulk density (g/ml) | Tapped density(g/ml) | Compressibility (%) | Hausners ratio |
|---------------------|-----------------------------|---------------------|----------------------|---------------------|----------------|
| F1 | 27.92 | 0.54 | 0.56 | 3.57 | 1.03 |
| F2 | 25.17 | 0.52 | 0.54 | 3.70 | 1.03 |
| F3 | 28.76 | 0.51 | 0.60 | 12 | 1.17 |
| F4 | 28.17 | 0.57 | 0.62 | 8.06 | 1.08 |
| F5 | 25.44 | 0.52 | 0.56 | 7.14 | 1.07 |
| F6 | 25 | 0.51 | 0.60 | 12 | 1.17 |

Table 7: Post compression parameters of tablets of formulations F1 to F6

| Formulation batch | Weight uniformity(mg) | Hardness kg/sq.in. | % friability | In-vitro dispersion time(sec) | Disintegration time(sec) | Wetting time(sec) | Drug content |
|-------------------|-----------------------|--------------------|--------------|-------------------------------|--------------------------|-------------------|---------------------|
| F1 | 201 ± 3.2 | 3.5 | 0.76 | 122 | 96 | 64 | 97.23 ± 0.21 |
| F2 | 203 ± 3.8 | 3.5 | 0.70 | 109 | 84 | 57 | 97.45 ± 0.89 |
| F3 | 201 ± 4.3 | 3.0 | 0.72 | 93 | 82 | 53 | 98.56 ± 0.89 |
| F4 | 202 ± 3.7 | 3.0 | 0.86 | 88 | 78 | 54 | 97.34 ± 0.31 |
| F5 | 201 ± 2.4 | 3.0 | 0.92 | 84 | 78 | 51 | 99.43 ± 0.81 |
| F6 | 202 ± 3.2 | 3.0 | 0.78 | 82 | 72 | 48 | 99.45 ± 0.42 |




Fig 3:Evaluation of wetting time for optimized batch F6




Fig 4: Evaluation of in-vitro dispersion time for optimized batch F6

Table 8: Comparative dissolution profiles of formulations F1 to F6

| S.No. | Formulation batch | 5 min | 10 min | 20 min | 30 min | 45 min | 60 min |
|-------|-------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 1. | F1 | 60.23± 0.03 | 62.25± 0.42 | 65.70± 0.26 | 76.52± 0.21 | 77.33± 0.13 | 78.33± 0.13 |
| 2. | F2 | 60.34± 0.08 | 64.57± 0.10 | 75.02± 0.07 | 79.21± 0.41 | 76.02± 0.07 | 75.98± 0.17 |
| 3. | F3 | 65.78± 0.07 | 76.67± 0.01 | 79.10± 0.17 | 79.29± 0.41 | 79.69± 0.09 | 78.68± 0.15 |
| 4. | F4 | 72.10± 0.06 | 75.74± 0.09 | 75.34± 0.22 | 74.73± 0.14 | 74.53± 0.12 | 80.10± 0.06 |
| 5. | F5 | 71.34± 0.22 | 72.96± 0.09 | 79.41± 0.05 | 80.45± 0.03 | 81.26± 0.03 | 82.46± 0.17 |
| 6. | F6 | 75.56± 0.03 | 78.97± 0.21 | 80.78± 0.19 | 81.33± 0.13 | 82.26± 0.03 | 85.46± 0.17 |

From the dissolution profile it was concluded that the tablet prepared by wet granulation technique, the formulation F6, containing 4% of

PEG 4000 and 7.5% cross carmilllose sodium showed maximum percentage (85.45%) drug release as compared to other formulations.




Fig 5: In-vitro release of Dabigatran from formulations F1 to F6

CHARACTERIZATION OF DRUG AND EXCIPIENTS

FT-IR spectroscopy

In order to characterize possible interactions between the drug and the polymeric carrier in the solid state, infrared spectra were recorded. In drug spectra, strong absorption bands were seen in the region 900 to 650 cm^{-1} indicating the presence of substituted benzene which is characteristic peaks for aromatic rings. [9]

The C=O stretching bands of acids are more intense and showed absorption bands at 1680-1760 cm^{-1} . The spectra showed characteristics peaks for aliphatic C-H stretching for CH₃ at 3000 cm^{-1} 3100 cm^{-1} and aromatic C-H stretch at 3083 cm^{-1} . The aromatic C=C stretching band was seen at 1450 to 1600 cm^{-1} . The NH stretching bands were seen at 3300 to 3500 cm^{-1} and NH bending band at 1555 cm^{-1} .

The important absorption peaks of drug in formulation remained at same position without significant change in peak intensity. No major distinctive alterations of absorption peaks of the drug were seen. [10]

In case of MCC: C-H stretching band is seen at 4270.40 cm^{-1} C-H bending band is seen at 1435.04 cm^{-1} . In case of crosscarmellose sodium the characteristic peak for NH bending at 1429.31 cm^{-1} . In case of crosspovidons the characteristic peak for NH stretching at 3398.72 cm^{-1} to 3457.55 cm^{-1} . In case of magnesium stearate the peaks at 1541.12 cm^{-1} NH bending, 2920.23 cm^{-1} , 2850.79 cm^{-1} C-H stretching and at 2850.79-2920.23 cm^{-1} , 1471689 cm^{-1} C-H banding.[11] Magnesium stearate with drug spectra reveals that the characteristics peaks of the formulation and the polymer are retained and no alteration of characteristic absorption peaks of the formulations are seen.

The peaks which are found in drug and polymers same peaks are found in optimized formulations of F1, F3, F6. [12, 13] There is no significant charges found. The result of study indicates absence of well defined chemical interaction between drug and polymers. The slight changes in peak intensity of drug with polymers indicate presence of some sort of interaction between drug and polymer which might be due to the intermolecular hydrogen bonding. [14, 15]




Fig: 6 FTIR spectra of Dabigatran.




Fig: 7 FTIR spectra of formulation F6




Fig: 8 FTIR spectra of PVP K-30




Fig: 9 FTIR spectra of MCC




Fig: 10 FTIR spectra of PEG 4000




Fig: 11 FTIR spectra of mannitol




Fig: 12 FTIR spectra of croscarmellose sodium




Fig: 13 FTIR spectra of crospovidone




Fig: 14 FTIR spectra of magnesium stearate




Fig: 15 FTIR spectra of Talc




Fig: 16 DSC thermogram of Dabigatran




Fig: 17 DSC thermogram of formulation F6

SUMMARY AND CONCLUSION

From the studies the following conclusions have been drawn

The fast dissolving tablets, when compared to other conventional dosage form have increased bio-availability, which may be attributed to direct absorption of drug into systemic circulation. The

fast dissolving absorption of drugs is expected to be rapid thus eliciting a fast therapeutic action. Hence, there is a need to develop a fast dissolving tablet containing anti-coagulant drug with immediate response, reduced manufacturing difficulties and cost effectiveness.

Dabigatran is an oral anti-coagulant drug requiring rapid onset of action to exert desired pharmacological effect. It is a lipophilic (BCS class-II) drug with little/no aqueous solubility, its absorption is dissolution rate limited and few reports are available in literature in support of this, increase in solubility of the drug is required to get rapid action. It has the half- life of 14. The total daily dose of Dabigatran is 50mg bid.

The purpose of this investigation was to develop fast dissolving tablets of Dabigatran to bypass first pass metabolism and to improve oral bio-availability for its immediate action for the treatment of stroke prevention in atrial fibrillation ; the fast dissolving tablets was formulated by wet granulation technique using hydrophilic carrier like PEG 4000 as solubilizer and POLYPLASDONE XL-10 (croscopovidone) and PRIMELLOSE (croscarmellose) used as super disintegrants with suitable concentration for quick dissolving tablets, allowing the API to be absorbed quickly to systemic circulation to show its immediate action.

- All the pre compression and post compression parameters were evaluated and found to be within the limit and meet the standard evaluation parameters with a slight deviation within a prescribed limit.

- The relative efficiency of these superdisintegrants were compared, it was concluded that the tablets prepared by wet granulation technique with PRIMILLOSE (7.5%) showed faster disintegration as compared to the other formulations.
- From the dissolution profile it was concluded that the tablet prepared by wet granulation technique, the formulation F₆ containing 4% of PEG 4000 and 7.5% PRIMELLOSE showed maximum percentage (85.46%) drug release due to its increase in porosity, wettability and dispersibility as compared to other formulations.
- From the DSC and FTIR study it was concluded that there was no possible drug and polymer interaction.
- From the above said it is concluded that the fast dissolving tablets of Dabigatran prepared with PRIMELLOSE and PEG 4000 by wet granulation method.

However, further studies are needed to comment. Further it is advised that the same work should be confirmed for its therapeutic efficacy where the in-vivo studies in human volunteers are required to correlate in vitro release data and clinical trials.

REFERENCES

- [1]. Weber and McCormack PL. Asenapine CNS drugs 23(9), 2009, 781-792
- [2]. Citrome L. Asenapine for schizophrenia and bipolar disorder. A review of the efficacy and safety profile.
- [3]. For this newly approved sublingually absorbed second generation anti-psychotic Int J Clin Pract 3(!@),2009, 1742-1784.
- [4]. W. Meltzer HY, Dritselis A, Yasothan U, et al, Asenapine nature Reviews 8, 2009, 843-844.
- [5]. European Directorate for quality of medicines, pharmaeuropa 104, 1998, 547
- [6]. <http://www.pheur.org>. Accessed 2007.
- [7]. Seager H. Drug delivery products and zydis fast dissolving dosage forms. J pharm pharmacol. 50, 1998, 375-382.
- [8]. Bradoo R, Shahani S, dewan B, sudarshan S fast dissolving drug delivery system. J Am Med Assoc India, 4(10), 2001, 27-31.
- [9]. Mizumoto T, Masuda Y. Takeshi Y, Estuo Y, katsuhide T, formulation design of a novel fast disintegrating tablet. Int Jpharm, 306(1-2), 2005, 83-90.
- [10]. G. Sandri, M.C. Bonferoni, F, Ferrari, s.Rossi, C. Caramella, Differentiating factors between oral fast dissolving technologies, Am. J. Drug deliv. 4(4), 2006, 249-262.
- [11]. Pharmaceutical and medical aspects of bioadhesive system for drug administration. Drug Dev. Ind. Pharm 14, 1988, 283-318.
- [12]. Fu, Y; Yang, S; Jeong, SH; Kimura, S and Park, K, Duchene D, touchard F, Peppar N.A.- 'orally fast disintegrating tablets developments technologies, taste making an clinical studies', Crit Rev Ther Drug Carrier Syst, 21, 2004, 433-476.

- [13]. International journal drug development and research October to 3(4), 2011, 36-44.
- [14]. Hiral brahmbhatt, FORMULATION AND EVALUATION OF SUBLINGUAL TABLET FOR NARATRIPTAN journal of drug delivery and therapeutics. 4, 2014, 19-23.
- [15]. N.R Sramika et al FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF TERAZOSIN HYDRO-CHLORIDE, IJPSR, 5(2), 2014, 417-427.
- [16]. Divya vishwakarma formulation and evaluation of metoprolol tartrate fast dissolving tablet, AJPTR 3(5), 2014 , 58-73.
- [17]. K.Patel Nibhal and SS.Pancholi An overview on sub lingual route for systemic drug delivery international journal of research in pharmaceutical and biomedical sciences, 3(2), 2012.